MediWound (NASDAQ:MDWD) Lowered to "Sell" Rating by Wall Street Zen

MediWound (NASDAQ:MDWD - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

A number of other equities research analysts also recently commented on the stock. Oppenheimer began coverage on shares of MediWound in a research report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 target price for the company. Alliance Global Partners initiated coverage on shares of MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 price objective for the company. Finally, HC Wainwright set a $31.00 price objective on shares of MediWound and gave the company a "buy" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, MediWound currently has an average rating of "Moderate Buy" and an average target price of $32.25.

MediWound Trading Up 2.0%

NASDAQ:MDWD opened at $20.46 on Friday. MediWound has a 12 month low of $14.14 and a 12 month high of $22.51. The company has a market cap of $221.17 million, a PE ratio of -9.79 and a beta of 0.32. The company has a 50 day simple moving average of $20.19 and a two-hundred day simple moving average of $18.46.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. The business had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. During the same quarter in the previous year, the firm posted ($1.05) EPS. Research analysts forecast that MediWound will post -2.66 earnings per share for the current year.

Institutional Trading of MediWound

Several hedge funds have recently bought and sold shares of MDWD. Silverberg Bernstein Capital Management LLC increased its holdings in shares of MediWound by 41.9% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 147,535 shares of the biopharmaceutical company's stock worth $2,858,000 after buying an additional 43,591 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 481 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares during the last quarter. Corebridge Financial Inc. increased its holdings in shares of MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 665 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of MediWound in the 1st quarter worth about $168,000. Hedge funds and other institutional investors own 46.83% of the company's stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.